Piper Sandler lowered the firm’s price target on Pacira to $62 from $63 and keeps an Overweight rating on the shares ahead of the Q1 results.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PCRX:
- Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023
- Pacira BioSciences Partners with The Invited Celebrity Classic – a PGA TOUR Champions Event – to Make iovera° The Official Non-Opioid Pain Management Partner
- Pacira partners with the Invited Celebrity Classic
- Pacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer
- Pacira BioSciences appoints Young as Chief Manufacturing Officer